Impact Factor 2.635 | CiteScore 2.99
More on impact ›

Opinion ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Neurol. | doi: 10.3389/fneur.2019.00973

Mutation load may reflect frequency, severity, and outcome of epilepsy in mt-DNA-related Leigh syndrome

  • 1K.A. Rasmussen (Norway), Norway

With interest we read the article by Lee et al. about 25 patients with Leigh syndrome (LS) due to mtDNA variants of whom 14 had epilepsy [1]. We have the following comments and concerns.
A main shortcoming of the study is that heteroplasmy rates of the mtDNA variants were not provided. It is also not mentioned if mtDNA was extracted from blood lymphocytes or from muscle or other tissues. Knowing heteroplasmy rates in various tissues is crucial as it may be one of the factors determining the phenotype and outcome.
LS may not only be due to mtDNA variants but also due to nDNA variants. We should be informed about which nDNA variants were found in the 100 patients who did not carry an mtDNA variant.
A shortcoming of the study is the absence of a comprehensive family history. We should know how many mothers of the 25 included patients were clinically affected or carried the mtDNA variant of their son. We should know if there were other first degree relatives with epilepsy or phenotypic features of a mitochondrial disorder (MID). According to table 1 the family history was negative for epilepsy in all 25 patients. This is quite unusual in the light that 75% of the MIDs due to mtDNA variants are maternally inherited [2].
In the abstract 14 of 25 patients had epilepsy but in the results section and table 1 only 32% of the 25 patients had seizures [1]. The authors should explain this discrepancy.
We should be informed why only 12 of the 14 patients with epilepsy received a treatment with anti-seizure drugs (ASDs). We should know if the two patients without ASDs were seizure free or if they or their parents refused ASD therapy.
We should know if the two patients on a ketogenic diet (KD) were the ones who did not receive an ASD treatment. It should be mentioned if the KD was effective and reduced seizure frequency in the two patients on KD as has been previously reported [3].
Rarely, patients with LS may develop stroke-like episodes (SLEs) [4] of which the stroke-like lesion (SLL) is the morphological equivalent on imaging [5]. We should know in how many of the 14 patients epilepsy or seizures were associated with a SLE, since seizures may trigger SLEs and vice versa.
Interestingly, the authors mention that >50% of the 125 patients received ophthalmologic treatment [1]. It should be indicted if patients had pigmentary retinopathy, glaucoma, cataract, optic atrophy, refractory errors, megalocornea, iris atrophy, pupillary dysfunction, cataract, ciliary body epithelial dysfunction, macular degeneration, retinal hypertrophy, choroidal atrophy or corneal ulcers and conjunctivitis, frequently found in MID patients [6].
LS is frequently a disease with poor prognosis [7]. Since mean follow-up duration was 5.7y it is quite likely that some of the initially included 25 patients deceased during follow-up. Thus, we should be informed how many of the 25 died during follow-up and which were the causes of death. According to table 1, one third of the patients had cardiac and one third had pulmonary involvement, which may significantly contribute to mortality of MID patients.
Overall, the study could be more meaningful if the various shortcomings were solved and if more data about family history, multiorgan involvement, mutation load, and outcome were provided.

Keywords: Leigh syndrome, Oxidative Phosphorylation, mtDNA, Anti-seizure drugs, respiratory chain

Received: 04 Jun 2019; Accepted: 27 Aug 2019.

Copyright: © 2019 Finsterer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Josef Finsterer, K.A. Rasmussen (Norway), Hamar, Norway, fipaps@yahoo.de